StreetInsider.com News Articles

Clearmind Medicine to acquire 51% of EV wireless charging firm

Fri, 04 Sep 2026 07:32:14 -0400

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, has signed a definitive agreement to acquire a 51% stake in Charging Robotics, a company that develops wireless charging systems for automated parking facilities and autonomous vehicles, according to a press release.

Under the terms of the deal, Clearmind will pay $2.5 million for the majority stake. In addition, Clearmind will extend a $1.5 million loan to Charging Robotics at an interest rate of 4% per annum. The loan is due on the three-year anniversary of the closing, with an automatic extension if Charging Robotics has not generated sufficient positive cash flow

Clearmind Medicine to acquire 51% of EV wireless charging firm

Fri, 04 Sep 2026 07:32:14 -0400

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

Fri, 04 Sep 2026 07:32:00 -0400

Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.

Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a definitive agreement (“Agreement”) to acquire a 51% stake in Charging Robotics, an intelligent

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

Fri, 04 Sep 2026 07:32:00 -0400

Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder

Tue, 01 Sep 2026 07:37:26 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) announced the initiation of Phase IIa of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD), according to a press release issued Sept. 1, 2026.

Six patients have been enrolled to date, with three participants at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. This marks the beginning of the first multiple-dose treatment phase, known as Part C, following the completion of the trial's initial safety phase conducted in healthy volunteers.

The Phase IIa trial is designed to evaluate the safety, tolerability, and preliminary

Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder

Tue, 01 Sep 2026 07:37:26 -0400

The Phase IIa trial is designed to evaluate the safety, tolerability, and preliminary

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Tue, 01 Sep 2026 07:37:00 -0400

Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with six patients enrolled to date. Three participants have been enrolled at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C (“phase

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Tue, 01 Sep 2026 07:37:00 -0400

Form 6-K Clearmind Medicine Inc. For: Aug 24

Mon, 24 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968003.html

Form 6-K Clearmind Medicine Inc. For: Aug 24

Mon, 24 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968003.html

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), and its collaborator Clearmind Medicine Inc. (NASDAQ: CMND) have had a U.S. patent application published covering a combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for potential use in treating post-traumatic stress disorder, anxiety, and eating disorders.

The United States Patent and Trademark Office published the application, which covers embodiments relating to the potential use of PEA in combination with MDMA, including potential effects on therapeutic potency, required dosing, side effects, and therapeutic window.

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation